AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23781982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS ipsilateral to the symptomatic ear (n=21)
Number of subjects: 40
Study 23781982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS contralateral to the symptomatic ear (n=19)
Number of subjects: 40
Study 22471135 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated threads moxibustion of Zhuang nationality
Number of subjects: 120
Study 22471135 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine and Caffeine tablets (oral administration)
Number of subjects: 120
Study 20937992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m² on day 1 and topotecan 0.75 mg/m² on days 1-5 followed by paclitaxel 175 mg/m² on day 1 and carboplatin (AUC = 5) on day 1 for four cycles, then four cycles of paclitaxel and carboplatin.
Number of subjects: 819
Study 20937992 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel for eight cycles.
Number of subjects: 819
Study 20937992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and topotecan followed by carboplatin and paclitaxel.
Number of subjects: 819
Study 20937992 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel.
Number of subjects: 819
Study 18260172 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate (2 mg every 2 months)
Number of subjects: 1395
Study 18260172 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate (3 mg every 3 months)
Number of subjects: 1395
Study 18260172 — intervention group
Group type: COMPARATOR
Intervention: Daily oral ibandronate (2.5 mg)
Number of subjects: 1395
Study 18260172 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1395
Study 18260172 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibandronate
Number of subjects: 1395
Study 16308255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine applied in the epipharyngeal space
Number of subjects: 98
Study 16308255 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 98
Study 16308255 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine and Control (placebo)
Number of subjects: 98
Study 16308255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Number of subjects: 98
Study 12798874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical removal of zona pellucida by using acidic Tyrode's solution
Number of subjects: 257
Study 12798874 — intervention group
Group type: COMPARATOR
Intervention: No removal (controls)
Number of subjects: 257
Study 12798874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical removal of zona pellucida in embryos with delayed development
Number of subjects: 257
Study 12798874 — intervention group
Group type: COMPARATOR
Intervention: No removal (controls) in embryos with delayed development
Number of subjects: 257
Study 10653210 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg sustained-release twice daily + 5 mg immediate-release with morning dose)
Number of subjects: 57
Study 10653210 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (15, 30, and 60 mg immediate-release in ascending doses)
Number of subjects: 57
Study 10653210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8704113 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostat 1000 dialysate monitoring device
Number of subjects: 29
Study 8704113 — intervention group
Group type: COMPARATOR
Intervention: Blood-side measurements
Number of subjects: 29
Study 30417842 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (Group 2)
Number of subjects: 132
Study 30417842 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltrate (Group 1)
Number of subjects: 132
Study 30417842 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltrate (Group 3)
Number of subjects: 132
Study 26771281 — intervention group
Group type: EXPERIMENTAL
Intervention: Current Nutrition Facts table (NFt)
Number of subjects: 26
Study 26771281 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Nutrition Facts tables (NFt)
Number of subjects: 26
Study 26771281 — intervention group
Group type: COMPARATOR
Intervention: Unequal serving sizes on NFts
Number of subjects: 26
Study 23916901 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary suturing (Group 1)
Number of subjects: 168
Study 23916901 — intervention group
Group type: COMPARATOR
Intervention: Non-suturing (Group 2)
Number of subjects: 168
Study 23916901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 168
Study 23011728 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (50 mg)
Number of subjects: 10
Study 23011728 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (150 mg)
Number of subjects: 10
Study 23011728 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (500 mg)
Number of subjects: 10
Study 23011728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23011728 — intervention group
Group type: COMPARATOR
Intervention: Prandial insulin
Number of subjects: 10
Study 17660722 — intervention group
Group type: EXPERIMENTAL
Intervention: Taiji-Qigong (TQ) training
Number of subjects: 49
Study 17660722 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WC) group
Number of subjects: 49
Study 15639293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (100 microg/week pegylated interferon alfa-2b and 100 mg/day lamivudine)
Number of subjects: 307
Study 15639293 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (100 microg/week pegylated interferon alfa-2b and placebo)
Number of subjects: 307
Study 15639293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 307
Study 15639293 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 307
Study 15639293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy and monotherapy
Number of subjects: 307
Study 12189483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic totally extraperitoneal prosthetic repair (TEPP)
Number of subjects: 39
Study 12189483 — intervention group
Group type: COMPARATOR
Intervention: Open Stoppa procedure
Number of subjects: 39
Study 12189483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 10437870 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 0
Study 7776170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic curets (U)
Number of subjects: 19
Study 7776170 — intervention group
Group type: COMPARATOR
Intervention: Manual curets (M)
Number of subjects: 19
Study 2140160 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis derivatives
Number of subjects: 0
Study 2140160 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0
Study 468749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 468749 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison boys
Number of subjects: 0
Study 31849035 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of oral hyoscine twice daily for 1 week, followed by once daily for 1 week
Number of subjects: 100
Study 31849035 — intervention group
Group type: COMPARATOR
Intervention: Routine expectant management
Number of subjects: 100
Study 28912358 — intervention group
Group type: EXPERIMENTAL
Intervention: COC plus spironolactone
Number of subjects: 46
Study 28912358 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 46
Study 25583916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling (7 sessions from antenatal to 6 months postpartum)
Number of subjects: 452
Study 25583916 — intervention group
Group type: COMPARATOR
Intervention: Routine counseling (equal number of sessions as intervention)
Number of subjects: 452
Study 25583916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling
Number of subjects: 452
Study 24881286 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 5% cream
Number of subjects: 350
Study 24881286 — intervention group
Group type: COMPARATOR
Intervention: Crotamiton 10% cream
Number of subjects: 350
Study 21275446 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil + amlodipine + HCTZ
Number of subjects: 0
Study 19025972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan at a dose of 1.2 mg/m2 twice daily for 5 days (Arm A)
Number of subjects: 90
Study 19025972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan once daily for 10 days (Arm B)
Number of subjects: 90
Study 19025972 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 90
Study 19025972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhematologic toxicity
Number of subjects: 90
Study 16406239 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial A1555G mutation screening in families with NSHL
Number of subjects: 100
Study 16406239 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of nuclear genes (GJB2, GJB3, GJB6)
Number of subjects: 100
Study 16406239 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of mitochondrial 12S rRNA gene
Number of subjects: 100
Study 16406239 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of tRNASer(UCN) gene
Number of subjects: 100
Study 15196585 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (0.25, 0.5, 1, 2.5, 5, or 10 mg) administered via 10 min i.v. infusion
Number of subjects: 94
Study 11513288 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized education program for paramedics
Number of subjects: 0
Study 9018183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 micrograms/dose) with the first and third dose of albuterol
Number of subjects: 90
Study 9018183 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo instead of ipratropium
Number of subjects: 90
Study 8359791 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (GH) for 2 years
Number of subjects: 0
Study 8359791 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 3488361 — intervention group
Group type: EXPERIMENTAL
Intervention: Microamperage electrical stimulation of trigger points with the Electro-Acuscope 80
Number of subjects: 50
Study 3488361 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 29419875 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL4*011 allele in ALL group
Number of subjects: 590
Study 29419875 — intervention group
Group type: COMPARATOR
Intervention: 10A type KIR2DL4 allele in ALL group
Number of subjects: 590
Study 29419875 — intervention group
Group type: COMPARATOR
Intervention: KIR2DL4 alleles in AML and CML groups
Number of subjects: 590
Study 27512827 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched spread
Number of subjects: 100
Study 27512827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (margarine spread without phytosterols)
Number of subjects: 100
Study 25634521 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural citric acid (harmless substance)
Number of subjects: 39
Study 25634521 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially harmful substance (agro-chemical acid)
Number of subjects: 39
Study 25634521 — intervention group
Group type: COMPARATOR
Intervention: Citric acid at C3 dose
Number of subjects: 39
Study 25634521 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 39
Study 22990631 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage with 10 ml/kg of normal saline
Number of subjects: 244
Study 22990631 — intervention group
Group type: COMPARATOR
Intervention: No gastric lavage (control group)
Number of subjects: 244
Study 20093904 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTEr study
Number of subjects: 1252
Study 20093904 — intervention group
Group type: EXPERIMENTAL
Intervention: TOMUS study
Number of subjects: 1252
Study 20093904 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior surgery for pelvic organ prolapse and SUI
Number of subjects: 1252
Study 18713273 — intervention group
Group type: EXPERIMENTAL
Intervention: MALP-2 (0.125-1 microg)
Number of subjects: 12
Study 18713273 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 12
Study 15829043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-ECG recorded by the patient and transmitted to a cardiology call centre
Number of subjects: 158
Study 15829043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-ECG
Number of subjects: 158
Study 11940070 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (cumulative dose of 25 mg administered in doses of 6.25 mg, 6.25 mg, and 12.5 mg)
Number of subjects: 104
Study 11940070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 10080652 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol (Painlax and Tramal)
Number of subjects: 0
Study 7583525 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) replacement therapy for 6 months
Number of subjects: 12
Study 7583525 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 12
Study 2076716 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal preparation of beta‐methasone dipropionate (0.039%)
Number of subjects: 20
Study 2076716 — intervention group
Group type: COMPARATOR
Intervention: Commercial propylene glycol-gel containing 0.064% beta‐methasone dipropionate
Number of subjects: 20
Study 7042366 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (200 mg q.i.d.)
Number of subjects: 30
Study 7042366 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg q.i.d.)
Number of subjects: 30
Study 7042366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31463614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 977
Study 31463614 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-diagnostic risk factors (financial stress, education level, exposure to traumatic events)
Number of subjects: 977
Study 31463614 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial stress
Number of subjects: 977
Study 31463614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education levels
Number of subjects: 977
Study 30835202 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) derived from GWAS (p<5×10‐05)
Number of subjects: 334398
Study 30835202 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple risk factors
Number of subjects: 334398
Study 31887169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin spray (800 μg, 2 puffs)
Number of subjects: 1107
Study 31887169 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 1107
Study 28629180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sausages enriched with approximately 250 mg EPA and DHA per 80 g daily for 8 weeks (n = 22)
Number of subjects: 44
Study 28629180 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo sausages (n = 22)
Number of subjects: 44
Study 24549261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclops group (15 knees with cyclops lesions)
Number of subjects: 55
Study 24549261 — intervention group
Group type: COMPARATOR
Intervention: No-cyclops group (40 knees without cyclops lesions)
Number of subjects: 55
Study 23455593 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) at HT7
Number of subjects: 25
Study 23455593 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 25
Study 20728875 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg twice daily DMXB-A
Number of subjects: 16
Study 20728875 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg twice daily DMXB-A
Number of subjects: 16
Study 20728875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19102866 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging ultrasonic integrated backscatter (IBS) in A group
Number of subjects: 72
Study 19102866 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging ultrasonic integrated backscatter (IBS) in B group
Number of subjects: 72
Study 16840741 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-driven weaning
Number of subjects: 144
Study 16840741 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physician-controlled weaning)
Number of subjects: 144
Study 12626975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LY315920Na/S-5920 (target plasma concentration of 200 ng/mL, n = 196)
Number of subjects: 586
Study 12626975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LY315920Na/S-5920 (target plasma concentration of 800 ng/mL, n = 194)
Number of subjects: 586
Study 12626975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 196)
Number of subjects: 586
Study 12626975 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose LY315920Na/S-5920 (n = 51)
Number of subjects: 586
Study 12626975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose LY315920Na/S-5920 (n = 48)
Number of subjects: 586
Study 12626975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 586
Study 11735710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene cream
Number of subjects: 349
Study 11735710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tazarotene cream
Number of subjects: 349
Study 11735710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tazarotene cream
Number of subjects: 349
Study 11735710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% tazarotene cream
Number of subjects: 349
Study 11735710 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin emollient cream
Number of subjects: 349
Study 11735710 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 349
Study 9709266 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammograms for women aged 40-49
Number of subjects: 0
Study 9709266 — intervention group
Group type: COMPARATOR
Intervention: Screening mammograms for women aged 50 and above
Number of subjects: 0
Study 8286827 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon (IFN)‐alpha
Number of subjects: 22
Study 2823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Red kidney beans breakfast meal
Number of subjects: 6
Study 2823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran cereal breakfast meal
Number of subjects: 6
Study 2823593 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread breakfast meal
Number of subjects: 6
Study 2823593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard whole-wheat-bread meal (4 hours later)
Number of subjects: 6
Study 29849105 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW-INR group (target INR 1.5-2.5)
Number of subjects: 148
Study 29849105 — intervention group
Group type: COMPARATOR
Intervention: CONVENTIONAL-INR group (target INR 2.0-3.0)
Number of subjects: 148
Study 27353466 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g, three times daily for 7 days
Number of subjects: 102
Study 27353466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 24245844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with preformulated implementation intentions added to the information leaflet
Number of subjects: 23182
Study 24245844 — intervention group
Group type: COMPARATOR
Intervention: Control group without implementation intentions
Number of subjects: 23182
Study 24245844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in the lowest socioeconomic status (SES) tertile
Number of subjects: 23182
Study 24245844 — intervention group
Group type: COMPARATOR
Intervention: Control in the lowest SES tertile
Number of subjects: 23182
Study 24245844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in the least deprived tertile
Number of subjects: 23182
Study 24245844 — intervention group
Group type: COMPARATOR
Intervention: Control in the least deprived tertile
Number of subjects: 23182
Study 24245844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention in the middle SES tertile
Number of subjects: 23182
Study 24245844 — intervention group
Group type: COMPARATOR
Intervention: Control in the middle SES tertile
Number of subjects: 23182
Study 22019438 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 22019438 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 30
Study 22019438 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 30
Study 22019438 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple+Spinach
Number of subjects: 30
Study 19875483 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min meal
Number of subjects: 17
Study 19875483 — intervention group
Group type: COMPARATOR
Intervention: 5-min meal
Number of subjects: 17
Study 17970818 — intervention group
Group type: EXPERIMENTAL
Intervention: proposed treatment method
Number of subjects: 0
Study 17970818 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study 16436240 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment with family involvement and social skills training)
Number of subjects: 547
Study 14583310 — intervention group
Group type: EXPERIMENTAL
Intervention: RHA-OPCAB
Number of subjects: 100
Study 14583310 — intervention group
Group type: COMPARATOR
Intervention: cCABG
Number of subjects: 100
Study 10787430 — intervention group
Group type: EXPERIMENTAL
Intervention: margarine with phytosterol esters (MSE) (1.84 g/d)
Number of subjects: 15
Study 10787430 — intervention group
Group type: EXPERIMENTAL
Intervention: margarine with phytostanol esters (MSA) (1.84 g/d)
Number of subjects: 15
Study 10787430 — intervention group
Group type: COMPARATOR
Intervention: margarine (M)
Number of subjects: 15
Study 8887803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing salivary peroxidase elements
Number of subjects: 0
Study 8887803 — intervention group
Group type: COMPARATOR
Intervention: Baseline values
Number of subjects: 0